Cencora, Inc. $COR Stock Holdings Lifted by Baader Bank Aktiengesellschaft

Key Points

• Baader Bank Aktiengesellschaft significantly increased its holdings in Cencora, Inc. by 318.5% during the second quarter, bringing its total shares to 4,336, valued at approximately $1.3 million.
• Analysts have a consensus rating of "Moderate Buy" for Cencora, with a consensus target price of $311.25, following several price target adjustments from firms including Wells Fargo and Morgan Stanley.
• Cencora recently reported earnings with an EPS of $4.00, exceeding estimates and reflecting an 8.7% increase in revenue compared to the same quarter last year.

Baader Bank Aktiengesellschaft increased its stake in Cencora, Inc. (NYSE:COR - Free Report) by 318.5% during the second quarter, according to its most recent filing with the SEC. The fund owned 4,336 shares of the company's stock after buying an additional 3,300 shares during the quarter. Baader Bank Aktiengesellschaft's holdings in Cencora were worth $1,300,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Bernard Wealth Management Corp. purchased a new position in Cencora during the fourth quarter valued at $67,000. Tidal Investments LLC lifted its holdings in Cencora by 3.1% in the 4th quarter. Tidal Investments LLC now owns 21,319 shares of the company's stock worth $4,790,000 after purchasing an additional 635 shares in the last quarter. Waverly Advisors LLC purchased a new stake in Cencora during the 4th quarter valued at $232,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Cencora by 6.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,648,451 shares of the company's stock valued at $370,374,000 after acquiring an additional 96,238 shares during the last quarter. Finally, PharVision Advisers LLC bought a new position in shares of Cencora during the 4th quarter worth $453,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on COR shares. Morgan Stanley set a $330.00 price objective on Cencora and gave the stock an "equal weight" rating in a research note on Wednesday, July 16th. Jefferies Financial Group raised their price objective on Cencora from $275.00 to $300.00 and gave the company a "hold" rating in a report on Monday, June 30th. Finally, Wells Fargo & Company raised their target price on Cencora from $337.00 to $354.00 and gave the company an "overweight" rating in a research report on Wednesday, August 13th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $311.25.

Cencora Trading Down 1.1%

Shares of COR stock traded down $3.23 during mid-day trading on Monday, hitting $286.80. 318,815 shares of the company's stock were exchanged, compared to its average volume of 1,579,302. Cencora, Inc. has a fifty-two week low of $218.65 and a fifty-two week high of $309.35. The stock has a 50-day simple moving average of $292.42 and a two-hundred day simple moving average of $287.29. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. The stock has a market cap of $55.60 billion, a price-to-earnings ratio of 29.52, a PEG ratio of 1.48 and a beta of 0.62.

Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share for the quarter, beating analysts' consensus estimates of $3.79 by $0.21. The firm had revenue of $80.66 billion for the quarter, compared to analysts' expectations of $80.34 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The firm's revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter last year, the firm earned $3.34 earnings per share. Equities analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th were given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend was Friday, August 15th. Cencora's payout ratio is presently 22.63%.

Insider Transactions at Cencora

In other Cencora news, CEO Robert P. Mauch sold 4,968 shares of Cencora stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $294.11, for a total value of $1,461,138.48. Following the completion of the transaction, the chief executive officer directly owned 42,351 shares in the company, valued at $12,455,852.61. The trade was a 10.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Chairman Steven H. Collis sold 31,350 shares of the business's stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the transaction, the chairman owned 305,913 shares of the company's stock, valued at approximately $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 65,475 shares of company stock worth $19,080,900. Corporate insiders own 10.80% of the company's stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.